Crossmark Global Holdings’s Core Laboratories CLB Stock Holding History

Crossmark Global Holdings’s Portfolio CLB Stock Details CLB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-4,170	Closed	-$287K	–	1390
2019 Q1	$287K	Buy	4,170 +130	+3%	+$8.71K	0.01%	1146
2018 Q4	$241K	Buy	4,040 +360	+10%	+$31.1K	0.01%	1198
2018 Q3	$426K	Sell	3,680 -1,230	-25%	-$139K	0.01%	1071
2018 Q2	$620K	Buy	4,910 +490	+11%	+$59.6K	0.02%	811
2018 Q1	$478K	Buy	4,420 +620	+16%	+$68.6K	0.01%	943
2017 Q4	$416K	Sell	3,800 -240	-6%	-$24K	0.01%	1127
2017 Q3	$399K	Buy	+4,040	New	+$392K	0.01%	1111
2016 Q3	$399K	Buy	+4,040	New	+$465K	0.01%	1111

Other funds holding CLB

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return

VanEck Associates New York $164B AUM 112.45% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Crossmark Global Holdings's CLB Position: Q2 2019 in Review

Crossmark Global Holdings sold out of Core Laboratories (CLB) in Q2 2019, closing a stake of 4,170 shares — an estimated $287K sold.

Crossmark Global Holdings first reported a position in CLB in Q3 2016 and held it in 8 quarters. The position peaked at $620K in Q2 2018. 304 funds tracked by Wall St. Rank hold CLB as of Q2 2019.

Crossmark Global Holdings reported no remaining Core Laboratories position as of Q2 2019 after selling out during the quarter.
Crossmark Global Holdings sold 4,170 Core Laboratories shares in Q2 2019, an estimated $287K.
Crossmark Global Holdings first reported a position in Core Laboratories in Q3 2016 and held it in 8 quarters.
Crossmark Global Holdings's Core Laboratories position peaked at $620K in Q2 2018.
304 funds tracked by Wall St. Rank held Core Laboratories as of Q2 2019.

Based on Crossmark Global Holdings's 13F filing for Q2 2019, filed 9 Jul 2019.